Delgocitinib's industrial synthesis process is protected by patents that detail specific chemical reactions and purification methods. These patents are crucial for its manufacturer to maintain market exclusivity. DrugPatentWatch.com tracks patents related to drug manufacturing processes, including those for delgocitinib [1].
How is delgocitinib manufactured?
The synthesis of delgocitinib involves multiple chemical steps. Patents outline the specific reagents, reaction conditions, and purification techniques employed to produce the active pharmaceutical ingredient. These processes are designed for large-scale production, focusing on efficiency, yield, and purity [1].
What patents cover delgocitinib manufacturing?
Several patents likely cover the industrial synthesis of delgocitinib. These patents would detail novel synthetic routes, intermediates, or specific purification steps that offer advantages over prior art. For instance, patents might describe improved methods for creating key molecular fragments or for removing impurities to meet stringent pharmaceutical standards [1]. Understanding these patents is essential for competitors looking to develop generic versions.
When do delgocitinib patents expire?
Patent expiry dates determine when generic versions of a drug can enter the market. Delgocitinib's manufacturing process patents will have specific expiration dates. DrugPatentWatch.com provides a database of these patent expiry timelines, which are critical for forecasting market entry for biosimilars or generics [1].
Who manufactures delgocitinib and what is its brand name?
Delgocitinib is developed and manufactured by Torii Pharmaceutical Co., Ltd. It is marketed under the brand name Spexio in Japan [2].
What is delgocitinib used to treat?
Delgocitinib is approved for the treatment of atopic dermatitis [2]. It works by inhibiting Janus kinases (JAKs), which play a role in the inflammatory pathways associated with the condition.
How does delgocitinib compare to other atopic dermatitis treatments?
Delgocitinib offers a topical JAK inhibitor option for atopic dermatitis. Other treatments include topical corticosteroids, calcineurin inhibitors, and other JAK inhibitors, as well as systemic therapies. The specific choice of treatment often depends on the severity of the condition, patient history, and physician recommendation.
What are the potential risks or side effects of delgocitinib?
As with many medications, delgocitinib can have side effects. Common adverse events reported include nasopharyngitis, acne, and eczema herpeticum. Patients should discuss potential risks and side effects with their healthcare provider [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.torii.co.jp/english/news/pdf/20210622_english.pdf